stage

Entac Medical Inc.

Entac Medical Inc.

location_on 东南 , 美国

概览商业计划书详情团队文件

请注意：
投资于早期阶段的企业存在风险，包括流动性不足、无分红、投资损失及股权稀释等。因此，此类投资应仅作为多元化投资组合的一部分进行。本平台仅面向具备足够专业知识、能够理解相关风险并自行作出投资决策的投资者。我们鼓励投资者自行审阅与评估各项投资，并根据自身判断决定是否参与。本网站所提供的信息仅供参考，我们无法保证其准确性或完整性。我们强烈建议投资者在进行任何投资前，与持牌专业人士完成尽职调查。本平台不提供任何法律或税务方面的建议。

简要概述

Entac develops AI-driven acoustic wearables predicting patient adverse events, with its first launched device, PrevisEA, targeting an $8 billion market and a pipeline for multiple high-value healthcare sectors exceeding $20 billion.

亮点

PrevisEA Commitments: 5 hospitals systems (63 hospitals) $41M revenue oppy
In review: 6 systems (71 hospitals) - $39M opportunity. Commitment due
Engaged: 7 systems (120 hospitals) - $67M opportunity - Expected in 2025.
Interest: 27 systems (328 hospitals)-$119M opportunity. Expected 2025-26.
80 systems (~1000 hospitals) engaged with PrevisEA at all sales stages

概览

目标	HK$ 16,000,000
最低标准。	HK$ 400,000
融资已到位。	HK$ 6,200,000
过往融资轮次	HK$ 62,000,000
阶段	实现销售
投资人角色	任何。

提出一个问题。
有問題嗎？

相似项目

Enertor Insoles

location_on东安格利亚, 英国

Transform sports recovery & performance with Enertor's PX1® insoles—revolutionary technology reducing impact by 51%. Endorsed by Usain Bolt, we aim to be the next £1B brand. Invest in innovation redefining running and injury prevention. Raised £330K✅

69% injury reduction proven in clinical trials with British Army
Endorsed by Usain Bolt; trusted by elite athletes worldwide
Rated best insoles by The New York Times and Runner's World

HK$3,200,000

融资目标

HK$55,000

最低投资额

Ostoform

location_on米德兰兹, 爱尔兰

Ostoform enables ostomy patients to live a life free from the worry of leaks and skin complications.

Product range developed and ready for commercial scale-up.
Distribution deals in place across 8 markets.
Reliable, recurring revenue streams in place.

HK$18,000,000

融资目标

HK$125,000

最低投资额

Kaya AI Healthtech

location_on北荷兰, 荷兰

Our AI removes clinician burdens so that patients can receive better personalised healthcare. We deliver faster, more accurate diagnosis and treatment planning, reducing delays and improving quality of life.

Specialist AI models cut diagnosis time from 15 mins to 5 seconds.
€3B SAM in EU dermatology & nutrition with clear expansion path.
CE mark path underway with pilots at leading Dutch hospitals.

HK$14,000,000

融资目标

HK$900,000

最低投资额